Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
CAMBRIDGE, Mass., Feb. 27, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor conferences in March. Details of the presentations are as follows:
| Cowen & Company 37th Annual Healthcare Conference | |||
| Date: | Monday, March 6, 2017 | ||
| Time: | 2:40 p.m. ET | ||
| Location: | Boston | ||
| Barclays Global Healthcare Conference 2017 | |||
| Date: | Thursday, March 16, 2017 | ||
| Time: | 9:30 a.m. ET | ||
| Location: | Miami | ||
Live webcasts of the presentations will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. Archived replays will be available for approximately 30 days following the respective presentations.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
